The Pharmagellan Guide to Biotech Forecasting and Valuation - David, Frank S.; Robey, Seth; Matthews, Andrew
108,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
payback
54 °P sammeln
  • Broschiertes Buch

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser-or aspire to be one-then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies. • Vetted benchmarks for key drivers of income, expenses, and valuation. • Proprietary analyses by Pharmagellan's experienced consulting team. • More than 150 current references from peer-reviewed…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
If you're a biotech executive, investor, deal maker, entrepreneur, or adviser-or aspire to be one-then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs. THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies. • Vetted benchmarks for key drivers of income, expenses, and valuation. • Proprietary analyses by Pharmagellan's experienced consulting team. • More than 150 current references from peer-reviewed research, industry white papers, and SEC filings. Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.